Slide 1: Cover letter to stock exchanges - Investor Presentation
January 28, 2025 To, The Manager BSE Limited Listing Department Corporate Relationship Department Floor National Stock Exchange of India Limited 25, P.J. Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Mumbai 400 001. Bandra (East), Mumbai 400 051. Symbol:
Slide 2: Investors' Presentation 9M FY25
Investors’ Presentation 9M FY25
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: Powered by Passion, Driven by Ethics
RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company APIs to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the Leader in Immunosuppressants b
Slide 6: RPG Life Sciences: Product Portfolio
RPG Life Sciences: Product Portfolio Strong ‘Textbook’ brands ; ↑ Chronic and Specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Textbook Brands Specialty Chronic Life Cycle Management Rheumatology (Existing Products) Trastuzumab Oncology A
Slide 7: Business Operations
Business Operations Z An @>9RPG Company ————— pe iE SCIENCES
Slide 8: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixation Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up
Slide 9: Building a Strong-Consistent-Profitable Business
Building a Strong-Consistent-Profitable Business 1 2 3 4 Driving Focusing Upticking Energizing Transformation Agenda on Execution Growth Trajectory Happy Teams 6 >10 6 >10 Targeted Tenets High Impact Projects Bold Moves Diverse Initiatives
Slide 10: Driving Transformation Agenda
1 Driving Transformation Agenda Tenet 1 Propel growth of DF Business Tenet 2 Accelerate Migration to Higher Margins Tenet 3 Build Strategic Assets/ Footprints Tenet 4 Accelerate IF Business Tenet 5 Embrace Digitalisation to transform Business Tenet 6 Strengthen organization to deliver core strategy
Slide 11: Focusing on Execution
2 Focusing on Execution Multiple Projects targeted to Transform Business, ↓ Costs, ↑ Quality, Add New Business 1 Comprehensive Business Transformation Project 6 Innovation Projects Plants Infra Modernization-Capacity Expansion 2 7 Digitalization Projects Projects 3 COGs Reduction Projects 8 M&A Proj
Slide 12: Upticking Growth Trajectory
3 Upticking Growth Trajectory Bold Move 1 Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation Bold Move 2 “Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn Bold Move 3 “Small Product” to Building “Mega Rx Portfolio of 100 cr +;
Slide 13: Energizing Happy Teams: Happiness Framework
Energizing Happy Teams: Happiness Framework 4 People Initiatives for a Building Happy Performance focussed Culture I Love My Work I Feel Valued RPGLS Heroes I am Growing Outperformance recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum Akanksha
Slide 14: Glimpses of Actions: Product Lifecycle Management - Naprosyn
Glimpses of Actions Product Lifecycle Management- Naprosyn LCM Strategy LCM Application to Legacy Brand - Naprosyn New Strengths New Dosage Forms New Molecule Combinations More New Indications to Follow New Customer Segments New Patient Segments On its way to become the 1st 100 Cr Brand New Geograph
Slide 15: Glimpses of Actions: Digitalization - RPG Serv
Glimpses of Actions: Sales and Marketing: Digitalization- RPG Serv RPG Serv: Anytime Anywhere Doctor Support Initiative 10 versions launched across 10 diverse Customer segments Therapy customization across services to ensure engagement >90K doctors enrolled- Excellent Feedback
Slide 16: Glimpses of Actions: AI at RPGLS - LSAI
Glimpses of Actions: Sales and Marketing : AI at RPGLS- LSAI
Slide 17: Manufacturing and Quality: Digitalization across Manufacturing Functions
Glimpses of Actions Manufacturing and Quality: Digitalization across Manufacturing Functions Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation • Operates Pumps • Safe, reliable, Scan
Slide 18: Glimpses of Actions: Sustainability - ESG Initiatives
Glimpses of Actions Sustainability- ESG Initiatives FY24 • Carbon emission reduction ↓15% (FY23); ↓27% (FY24) Environmental • Energy Efficiency: Energy Efficient pumps ; Leakages rectification of compressed air system; High Efficiency ↑8% (FY23); ↑26% (FY24) chillers/Brine Plant ↓7% (FY23); ↓16% (FY
Slide 19: HR: Monthly Townhalls
Glimpses of Actions HR: Monthly Townhalls Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie 140+ 100+ Awards Recognitions 1000+ colleagues Celebrated
Slide 20: HR: Employee Development, Motivation and Engagement
Glimpses of Actions HR: Employee Development, Motivation and Engagement Rewards and Recognition: Hi-Flier Function Employee Engagement Crowdsourcing Ideas Employee Motivation
Slide 21: Financial Performance
Financial Performance Z An FPG Company ———— PG LIFE SCIENCES
Slide 22: Q3 FY25 Performance
Q3 FY25 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 172.7 46.9 153.7 35.5 52.5 39.8 23.1% 27.1% 30.4% 25.9% Q3 FY24 Q3 FY25 Q3 FY24 Q3 FY25 Q3 FY24 Q3 FY25 PAT & PAT Margin EPS 34.9 21.1 26.5 16.0 20.2% 17.2% Q3 FY24 Q3 FY
Slide 23: 9M FY25 Performance
9M FY25 Performance Figures in circle are Margins (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 510.3 455.1 125.3 141.8 100.1 113.0 98.0 27.8% 24.5% 24.8% 22.0% 19.2% 9M FY24 9M FY25 9M FY24 9M FY25 9M FY24 9M FY25 9MFY25 (Adj) EPS PAT
Slide 24: Key Financials Yearly Trends
Key Financials Yearly Trends An Un-interrupted Upward Trajectory Continues Unabated Figures in circle are Margins (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 135.4 141.8 125.3 117.8 582.1 107.5 512.8 510.3 89.4 91.7 440.2 70.8 73.2 37
Slide 25: Margins Yearly Trends - at a glance
Margins Yearly Trends- at a glance An Uninterrupted Upward Trajectory continues- EBITDA crosses 27%; PBT* crosses 24% and PAT* crosses 18% * Adjusted EBITDA% 27.8% 23.3% PBT%* 24.5% 20.3% 21.0% 20.2% 18.2% 16.6% PAT%* 17.9% 18.2% 15.9% 15.1% 13.8% 11.7% 13.2% 11.1% 11.1% 10.4% 10.3% 9.8% 9.3% 8.1% 8
Slide 26: Key Financial Ratios Yearly Trends (ROCE, ROE, D/E)
Key Financial Ratios Yearly Trends (ROCE, ROE, D/E) Upward Trajectory continues ROCE% ROE% Debt/Equity Ratio 31.0% 29.7% 23.4% 28.5% 22.0% 24.9% 20.1% 0.22 18.5% 20.9% 16.4% 0.06 9.7% 6.7% 0.01 0.00 0.00 0.00 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 C
Slide 27: 9M FY25: Business Segment-wise Performance
9M FY25: Business Segment-wise Performance Domestic Formulations contributed 66% to total sales of 9M FY25 • 12% sales growth driven by both Legacy and New products 330.6 Domestic 294.6 • Growth consistently higher than the market Business Segments Formulations • New products* contribution improving
Slide 28: ICRA Rating Upgradation in FY24
RPG Life Sciences ICRA Rating Upgradation in FY24 A- (FY19) to A(FY21) to A+ (FY24) Long term rating recently upgraded to A+ from A Short term rating reaffirmed at A1 Outlook on long-term rating has been retained as Stable The rating upgradation factors: • Strong brands in the Indian Pharmaceutical
Slide 29: Business Strategy
Business Strategy Z 28 An @>F@PG Company = ———————————————————— RPG LIFE SCIENCES
Slide 30: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Textbook Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage - Cardiolo
Slide 31: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 32: APIs Business: Business Strategy and Way Forward
APIs Business: Business Strategy and Way Forward • High value, low volume, niche APIs • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus – long-l
Slide 33: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities 32
Slide 34: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • Modernization cum Capacity Expansion underway
Slide 35: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly internal audit of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market
Slide 36: Awards & Recognitions
Awards & Recognitions Z An @>F@P@G Company ———— PG LIFE SCIENCES
Slide 37: Recognized as India's Top Value Creators by Dun & Bradstreet
RPG Life Sciences recognized as India’s Top 500 Value Creators by Dun & Bradstreet
Slide 38: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22)
Slide 39: RPG Life Sciences Bagged Top Awards of the Industry
RPG Life Sciences Bagged Top Awards of the Industry Best Patent Award Best Corporate Citizen Award
Slide 40: New Launch Naprosyn+ bags Brand Award
New Launch Naprosyn+ bags Brand Award
Slide 41: Journey Ahead
Journey Ahead Z An @>F@PG Company = ——————————————————————— RPG LIFE SCIENCES
Slide 42: Transformation Agenda will continue to drive All-Round Performance
Transformation Agenda will continue to drive All-Round Performance Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measures both in Opex Fram
Slide 43: 7 Pillars Identified to Scale-up Business
Diligent work on the Comprehensive 7 Pillars identified to Scale-up” business 1 2 3 4 5 6 7 State-of-art Targeted Lead Therapy Talent Institutionalized TECHNOLOGY ↑ Capacity Niche- focus M&As ADJACENT Development INNOVATION enablement PLANTS R&D PIPELINE Spaces /Acquisition • Focused New • Instituti
Slide 44: RPG Life Sciences
800006 000 Z An FPG Company RPG LIFE SCIENCES